To asses social and clinical correlates of neoadjuvant chemotherapy (NAC) utilization among Medicare beneficiaries.
A cohort of SEER-Medicare (2004-2015) patients with muscle-invasive bladder cancer treated by radical cystectomy were stratified into three-groups: standard of care NAC (cisplatin-based combination), non-standard of care NAC, and upfront cystectomy.